The estimated Net Worth of Roy Winston is at least $5.6 Milion dollars as of 2 August 2023. Mr. Winston owns over 509 units of Pacira BioSciences Inc stock worth over $681,720 and over the last 5 years he sold PCRX stock worth over $3,310,256. In addition, he makes $1,611,800 as Chief Clinical Officer at Pacira BioSciences Inc.
Roy has made over 10 trades of the Pacira BioSciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 509 units of PCRX stock worth $17,754 on 2 August 2023.
The largest trade he's ever made was selling 22,224 units of Pacira BioSciences Inc stock on 31 March 2021 worth over $1,569,237. On average, Roy trades about 4,635 units every 109 days since 2019. As of 2 August 2023 he still owns at least 52,440 units of Pacira BioSciences Inc stock.
You can see the complete history of Mr. Winston stock trades at the bottom of the page.
Roy Winston serves as Chief Clinical Officer of the Company. He previously served as our Senior Vice President, Anesthesia, Surgery and Medical Affairs from December 2017 until August 2018 and as our Vice President, Anesthesia & Surgical Services from April 2017 until December 2017. Prior to joining Pacira, he founded LaserAway, a national aesthetic dermatology group, and served as its chief executive officer from January 2005 until March 2007. Dr. Winston has served as chief executive officer and president of LaserAway Medical Corp., the management group of LaserAway, since January 2005. Dr. Winston holds a B.A. from the University of Pennsylvania and an M.D. from the Icahn School of Medicine at Mount Sinai.
As the Chief Clinical Officer of Pacira BioSciences Inc, the total compensation of Roy Winston at Pacira BioSciences Inc is $1,611,800. There are 4 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
Roy Winston is 59, he's been the Chief Clinical Officer of Pacira BioSciences Inc since 2018. There are 9 older and 12 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Roy's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon oraz Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: